Nasdaq Regulation



Eun Ah ChoiSenior Vice President
U.S. Listing Qualifications & Market Surveillance

November 16, 2023

Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549

Division of Corporation Finance:

This is to certify that on November 15, 2023, The Nasdaq Stock Market LLC (the "Exchange") received from Revolution Medicines, Inc. (the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following securities:

Warrants to purchase 0.1112 shares of common stock expiring 2026

We further certify that the security described above has been approved by the Exchange for listing and registration upon official notice of issuance.

We understand that the Registrant is seeking immediate acceleration of the effective date of registration, and we hereby join in such request.

Sincerely,

En Sh Chri

№ Nasdaq Nasdaq Regulation